Analyst Mark Massaro of BTIG reiterated a Buy rating on Guardant Health (GH – Research Report), retaining the price target of $50.00.

Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. IDEAYA Biosciences ... International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., ...

With more than 10 miles of Bay shoreline, a Redwood City Council study session focused on its vulnerability to sea-level rise ...

Exact Sciences Corp ( (EXAS)) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its investors. Exact Sciences Corp. is a prominent company in ...

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present three abstracts highlighting significant advancements in the development of a ...

Exact Sciences reports quarterly GAAP losses of 21 cents per share, which missed the analyst consensus estimate for losses of 20 cents. Quarterly sales of $709 million miss the consensus estimate ...

Two next-door neighbors recently opened up a European-style bakery in Redwood City, aptly named The Baker Next Door. About 10 years ago, when then-San Francisco residents Jenna Johnson and her ...

Exact Sciences reported third-quarter results that fell short of analyst expectations and cut its guidance for the fourth quarter. The cut, which William Blair analysts called a “shocking ...

Redwood City has a new Peruvian and Latin American restaurant. The seventh Bay Area location of Limón debuted in the Peninsula city last month, serving up dishes such as ceviche and lomo saltado ...

This article updates the investment merits of Exact Sciences following its disappointing Q3, 2024 earnings. Recent approval of an improved version of its lead product will not show up in revenues ...

Exact Sciences Corporation EXAS reported a net loss of 21 cents in third-quarter 2024 compared with break-even earnings in the year-ago quarter. The figure was wider than the Zacks Consensus ...

Exact Sciences' Q3 earnings report has led to a ~25% drop in its share price, due to a slight guidance cut and narrow revenue miss. Despite impressive historic revenue growth, Exact faces ...